Business Context and Reporting Period
Company: Myriad Genetics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1999
Business Overview: Myriad Genetics operates in two primary segments: research (gene discovery, sequencing, and therapeutic development) and molecular diagnostics (testing for disease predisposition, notably BRACAnalysis for breast/ovarian cancer and CardiaRisk for cardiovascular disease). The company relies heavily on collaborative research agreements with major pharmaceutical entities (e.g., Novartis, Bayer, Schering) for funding and revenue.
Key Financial Metrics
| Metric | Q3 1999 | Q3 1998 |
|---|---|---|
| Total Revenues | $6,861,931 | $5,559,986 |
| Net Loss | ($2,191,092) | ($2,702,502) |
| Operating Loss | ($2,749,787) | ($3,415,791) |
| Net Cash from Operating Activities | $8,309,851 | ($4,506,201) |
| Cash and Cash Equivalents (End of Period) | $15,677,896 | $9,230,572 |
| Accumulated Deficit | ($46,130,972) | N/A |
| Loss Per Share (Basic & Diluted) | ($0.23) | ($0.29) |
Liquidity: Total current assets were $31.6 million against current liabilities of $14.4 million. The company holds significant marketable investment securities ($30.8 million total).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 23% year-over-year. Research revenue rose to $5.2 million (from $4.6 million), driven by a new collaboration with Novartis Agricultural Discovery Institute (NADII). Molecular diagnostic revenue surged 77% to $1.6 million, attributed to increased sales of BRACAnalysis and CardiaRisk tests.
- Improved Operating Cash Flow: Operating cash flow swung from a $4.5 million outflow in Q3 1998 to an $8.3 million inflow in Q3 1999. This was primarily due to a $9.5 million increase in deferred revenue resulting from an $11.5 million upfront payment from the NADII agreement.
- Expense Management: Research and development expenses remained relatively flat ($5.8 million) despite new projects, due to increased automation. Selling, general, and administrative (SG&A) expenses increased 18% to $3.0 million, partly due to a one-time asset write-off of $344,531.
- Reduced Net Loss: Net loss improved by approximately $511,000 compared to the prior year quarter.
Guidance, Outlook, and Risks
- Outlook: Management expects to incur losses for at least the next several years due to R&D expansion, staffing costs, and facility growth. Capital resources are deemed adequate for at least two years.
- New Collaborations:
- NADII: $33.5 million agreement for genomic research on cereal crops (upfront payment received).
- Schering Berlin: Subsequent event (October 1999) involving a $5 million stock sale and expanded cardiovascular research collaboration.
- Peter Friedli: September 1999 private placement of 355,000 shares for ~$5 million.
- Risks:
- Year 2000 Issue: Company is substantially ready, but risks remain regarding supplier/customer failures which could disrupt operations or invoicing.
- Reimbursement: Uncertainty regarding government and private insurer reimbursement for genetic tests.
- Competition: Intense competition in gene discovery and potential inability to secure rights to critical genes.
- Regulatory: Uncertainty regarding future government regulation of the business.
Investor Verification Checklist
- Deferred Revenue Recognition: Verify the amortization schedule for the $11.5 million NADII upfront payment to understand future revenue recognition patterns.
- One-Time Expenses: Confirm the nature and impact of the $344,531 asset write-off included in SG&A expenses.
- Subsequent Stock Sales: Review the terms of the October 1999 sale to Schering Berlin ($5 million for 303,030 shares) and the September sale to Peter Friedli to assess dilution and valuation.
- Year 2000 Compliance: Validate the status of third-party supplier readiness, as the company notes risks beyond its direct control.
- Collaboration Milestones: Monitor progress on major agreements (Novartis, Bayer, Schering) to assess the likelihood of receiving potential milestone payments totaling hundreds of millions.